Influenza virus neuraminidase (NA)

a target for antivirals and vaccines

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Influenza, the most common infectious disease, poses a great threat to human health because of its highly contagious nature and fast transmissibility, often leading to high morbidity and mortality. Effective vaccination strategies may aid in the prevention and control of recurring epidemics and pandemics associated with this infectious disease. However, antigenic shifts and drifts are major concerns with influenza virus, requiring effective global monitoring and updating of vaccines. Current vaccines are standardized primarily based on the amount of hemagglutinin, a major surface antigen, which chiefly constitutes these preparations along with the varying amounts of neuraminidase (NA). Anti-influenza drugs targeting the active site of NA have been in use for more than a decade now. However, NA has not been approved as an effective antigenic component of the influenza vaccine because of standardization issues. Although some studies have suggested that NA antibodies are able to reduce the severity of the disease and induce a long-term and cross-protective immunity, a few major scientific issues need to be addressed prior to launching NA-based vaccines. Interestingly, an increasing number of studies have shown NA to be a promising target for future influenza vaccines. This review is an attempt to consolidate studies that reflect the strength of NA as a suitable vaccine target. The studies discussed in this article highlight NA as a potential influenza vaccine candidate and support taking the process of developing NA vaccines to the next stage.

Original languageEnglish
Pages (from-to)2087-2094
Number of pages8
JournalArchives of Virology
Volume161
Issue number8
DOIs
Publication statusPublished - 01-08-2016

Fingerprint

Neuraminidase
Orthomyxoviridae
Antiviral Agents
Vaccines
Influenza Vaccines
Human Influenza
Communicable Diseases
Hemagglutinins
Pandemics
Drug Delivery Systems
Surface Antigens
Immunity
Catalytic Domain
Vaccination
Morbidity
Mortality
Antibodies
Health

All Science Journal Classification (ASJC) codes

  • Virology

Cite this

@article{0ece000e446c4b47bc12cb33a4b6fa69,
title = "Influenza virus neuraminidase (NA): a target for antivirals and vaccines",
abstract = "Influenza, the most common infectious disease, poses a great threat to human health because of its highly contagious nature and fast transmissibility, often leading to high morbidity and mortality. Effective vaccination strategies may aid in the prevention and control of recurring epidemics and pandemics associated with this infectious disease. However, antigenic shifts and drifts are major concerns with influenza virus, requiring effective global monitoring and updating of vaccines. Current vaccines are standardized primarily based on the amount of hemagglutinin, a major surface antigen, which chiefly constitutes these preparations along with the varying amounts of neuraminidase (NA). Anti-influenza drugs targeting the active site of NA have been in use for more than a decade now. However, NA has not been approved as an effective antigenic component of the influenza vaccine because of standardization issues. Although some studies have suggested that NA antibodies are able to reduce the severity of the disease and induce a long-term and cross-protective immunity, a few major scientific issues need to be addressed prior to launching NA-based vaccines. Interestingly, an increasing number of studies have shown NA to be a promising target for future influenza vaccines. This review is an attempt to consolidate studies that reflect the strength of NA as a suitable vaccine target. The studies discussed in this article highlight NA as a potential influenza vaccine candidate and support taking the process of developing NA vaccines to the next stage.",
author = "Anitha Jagadesh and Salam, {Abdul Ajees Abdul} and Mudgal, {Piya Paul} and Govindakarnavar Arunkumar",
year = "2016",
month = "8",
day = "1",
doi = "10.1007/s00705-016-2907-7",
language = "English",
volume = "161",
pages = "2087--2094",
journal = "Archives of Virology",
issn = "0304-8608",
publisher = "Springer Wien",
number = "8",

}

Influenza virus neuraminidase (NA) : a target for antivirals and vaccines. / Jagadesh, Anitha; Salam, Abdul Ajees Abdul; Mudgal, Piya Paul; Arunkumar, Govindakarnavar.

In: Archives of Virology, Vol. 161, No. 8, 01.08.2016, p. 2087-2094.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Influenza virus neuraminidase (NA)

T2 - a target for antivirals and vaccines

AU - Jagadesh, Anitha

AU - Salam, Abdul Ajees Abdul

AU - Mudgal, Piya Paul

AU - Arunkumar, Govindakarnavar

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Influenza, the most common infectious disease, poses a great threat to human health because of its highly contagious nature and fast transmissibility, often leading to high morbidity and mortality. Effective vaccination strategies may aid in the prevention and control of recurring epidemics and pandemics associated with this infectious disease. However, antigenic shifts and drifts are major concerns with influenza virus, requiring effective global monitoring and updating of vaccines. Current vaccines are standardized primarily based on the amount of hemagglutinin, a major surface antigen, which chiefly constitutes these preparations along with the varying amounts of neuraminidase (NA). Anti-influenza drugs targeting the active site of NA have been in use for more than a decade now. However, NA has not been approved as an effective antigenic component of the influenza vaccine because of standardization issues. Although some studies have suggested that NA antibodies are able to reduce the severity of the disease and induce a long-term and cross-protective immunity, a few major scientific issues need to be addressed prior to launching NA-based vaccines. Interestingly, an increasing number of studies have shown NA to be a promising target for future influenza vaccines. This review is an attempt to consolidate studies that reflect the strength of NA as a suitable vaccine target. The studies discussed in this article highlight NA as a potential influenza vaccine candidate and support taking the process of developing NA vaccines to the next stage.

AB - Influenza, the most common infectious disease, poses a great threat to human health because of its highly contagious nature and fast transmissibility, often leading to high morbidity and mortality. Effective vaccination strategies may aid in the prevention and control of recurring epidemics and pandemics associated with this infectious disease. However, antigenic shifts and drifts are major concerns with influenza virus, requiring effective global monitoring and updating of vaccines. Current vaccines are standardized primarily based on the amount of hemagglutinin, a major surface antigen, which chiefly constitutes these preparations along with the varying amounts of neuraminidase (NA). Anti-influenza drugs targeting the active site of NA have been in use for more than a decade now. However, NA has not been approved as an effective antigenic component of the influenza vaccine because of standardization issues. Although some studies have suggested that NA antibodies are able to reduce the severity of the disease and induce a long-term and cross-protective immunity, a few major scientific issues need to be addressed prior to launching NA-based vaccines. Interestingly, an increasing number of studies have shown NA to be a promising target for future influenza vaccines. This review is an attempt to consolidate studies that reflect the strength of NA as a suitable vaccine target. The studies discussed in this article highlight NA as a potential influenza vaccine candidate and support taking the process of developing NA vaccines to the next stage.

UR - http://www.scopus.com/inward/record.url?scp=84973137365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84973137365&partnerID=8YFLogxK

U2 - 10.1007/s00705-016-2907-7

DO - 10.1007/s00705-016-2907-7

M3 - Review article

VL - 161

SP - 2087

EP - 2094

JO - Archives of Virology

JF - Archives of Virology

SN - 0304-8608

IS - 8

ER -